Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

518 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Fujiwara SI, Shirato Y, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Fujiwara SI, et al. Among authors: yamasaki r. Int J Hematol. 2018 Jun;107(6):712-715. doi: 10.1007/s12185-017-2378-y. Epub 2017 Nov 28. Int J Hematol. 2018. PMID: 29185155
Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Ashizawa M, Yamamoto C, Fujiwara S, Okazuka K, Hatano K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kako S, Kanda Y. Sugimoto M, et al. Among authors: yamasaki r. Ann Hematol. 2016 Sep;95(9):1513-9. doi: 10.1007/s00277-016-2740-9. Epub 2016 Jul 1. Ann Hematol. 2016. PMID: 27365141
Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia.
Ito S, Fujiwara SI, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Ito S, et al. Among authors: yamasaki r. Ann Hematol. 2017 May;96(5):719-724. doi: 10.1007/s00277-017-2933-x. Epub 2017 Feb 1. Ann Hematol. 2017. PMID: 28144729 Review.
Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Umino K, et al. Among authors: yamasaki r. Hematology. 2017 Oct;22(9):521-526. doi: 10.1080/10245332.2017.1312204. Epub 2017 Apr 17. Hematology. 2017. PMID: 28413914 Free article.
Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia.
Minakata D, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Minakata D, et al. Among authors: yamasaki r. Int J Hematol. 2017 Sep;106(3):411-417. doi: 10.1007/s12185-017-2251-z. Epub 2017 May 15. Int J Hematol. 2017. PMID: 28508228
Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement.
Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Umino K, et al. Among authors: yamasaki r. Hematology. 2018 Sep;23(8):470-477. doi: 10.1080/10245332.2018.1446279. Epub 2018 Feb 28. Hematology. 2018. PMID: 29486661 Free article. Review.
Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies.
Minakata D, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ohmori T, Kanda Y. Minakata D, et al. Among authors: yamasaki r. Int J Hematol. 2019 Feb;109(2):141-146. doi: 10.1007/s12185-018-02567-w. Epub 2018 Dec 8. Int J Hematol. 2019. PMID: 30536180
Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
Kawasaki Y, Kimura SI, Nakano H, Mashima K, Shirato Y, Kawaguchi SI, Toda Y, Ochi SI, Nagayama T, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Fujiwara SI, Ohmine K, Kako S, Muroi K, Kanda Y. Kawasaki Y, et al. Among authors: yamasaki r. Int J Hematol. 2019 Apr;109(4):470-476. doi: 10.1007/s12185-019-02593-2. Epub 2019 Jan 25. Int J Hematol. 2019. PMID: 30684252
Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation.
Yamamoto C, Nakashima H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Mashima K, Nagayama T, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Sugimoto M, Ishihara Y, Ashizawa M, Hatano K, Sato K, Oh I, Fujiwara SI, Ueda M, Ohmine K, Muroi K, Kanda Y. Yamamoto C, et al. Among authors: yamasaki r. Blood Adv. 2019 Nov 12;3(21):3266-3277. doi: 10.1182/bloodadvances.2019000745. Blood Adv. 2019. PMID: 31698458 Free PMC article.
The impact of overweight on renal toxicity in patients treated with dexamethasone, high-dose cytarabine, and cisplatin.
Umino K, Hatano K, Ochi SI, Genda H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Minakata D, Nakano H, Yamasaki R, Morita K, Yamamoto C, Ashizawa M, Sato K, Oh I, Fujiwara SI, Ohmine K, Muroi K, Kanda Y. Umino K, et al. Among authors: yamasaki r. Int J Hematol. 2020 Mar;111(3):396-400. doi: 10.1007/s12185-019-02779-8. Epub 2019 Nov 14. Int J Hematol. 2020. PMID: 31728828
518 results